Common tumor-associated antigen (TAA) targets include CEA, HER2, GPC3, EpCAM, etc. are often expressed on vital organs, which severely limit the application of CAR-T in solid tumors.162 The continuous discovery of highly expressed and CAR-T-developable targets has led to rapid growth of clinical pipelines, such as GPC3 highly expressed in liver cancer, CLDN18.2 highly expressed in gastric and pancreatic cancer, EGFRvIII in glioblastoma.163,164. Here, GPC3 is linked to liver cancer.